<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-20240" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Antineutrophil Cytoplasmic Antibodies (ANCA) Test</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Khalid</surname>
            <given-names>Noman</given-names>
          </name>
          <aff>Shaikh Zayed Hospital Lahore</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Aeddula</surname>
            <given-names>Narothama R.</given-names>
          </name>
          <aff>Deaconess HS, IN University School Med</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Noman Khalid declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Narothama Aeddula declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>11</day>
          <month>8</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-20240.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>The human body is designed to fight against infections and kill cancer cells. An essential feature of the human immune system is recognizing and distinguishing between its cells (known as 'self') and foreign cells like bacteria and viruses (known as 'non-self'). Every cell has proteins related to their origin and functioning environment, called antigens, that differentiate between self and&#x000a0;non-self by the immune system. As a component of the immune system, antibodies or immunoglobulins are proteins produced by immune cells called B Lymphocytes, which eventually convert into plasma cells. These antibodies are mainly produced during exposure to infection or by binding to antigens; their job is to neutralize or eliminate non-self-entities entering the body. Antibodies are also produced via vaccination by either exposure to killed antigens or direct inoculation of already formed antibodies in vitro.</p>
        <p>The immune system's failure to recognize 'self' is called autoimmunity, in which the immune system attacks some human body tissues and destroys them. In autoimmunity, there is the formation of antibodies against self-antigens called autoantibodies. These autoantibodies form against one type of cell to which they bind and destroy.</p>
        <p>Antineutrophil cytoplasmic antibodies (ANCAs) are specific antibodies formed against cytoplasmic granules (antigens) of polymorphonuclear neutrophil granulocytes (PMNs).<xref ref-type="bibr" rid="article-20240.r1">[1]</xref>&#x000a0;These autoantibodies are present in ANCA-associated small-vessel vasculitides. The applied use of ANCA lab testing, which detects ANCA autoantibodies, is used to diagnose several vasculitis diseases, primarily pauci-immune small vessel vasculitides granulomatosis with polyangiitis (GPA, previously called Wegener granulomatosis), microscopic polyangiitis (MPA), and to lesser extent eosinophilic granulomatosis with polyangiitis (eg, Churg-Strauss syndrome) and anti-Goodpasture disease.<xref ref-type="bibr" rid="article-20240.r1">[1]</xref><xref ref-type="bibr" rid="article-20240.r2">[2]</xref></p>
      </sec>
      <sec id="article-20240.s2" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Neutrophils are the most abundant leukocyte type, comprising 50% to 75% of the white blood cell population. About 1800 to 8000 neutrophils are normally present per microliter of blood; their number can increase 10-fold under infectious conditions. Neutrophils contain 2 main types of granules: 1) peroxidase-positive (azurophilic), and 2) peroxidase-negative. Both ANCA-myeloperoxidase (MPO) and ANCA-proteinase 3 (PR3) are enzymes present in peroxidase-positive granules, and MPO is the most prevalent granular protein. PR3 is important for serving as a hematopoietic regulator and has apoptosis-inducing capabilities. Some less specific ANCA antigens include cathepsin G, lactoferrin, elastase, defensin, &#x003b1;-enolase, moesin, leukocidin, bactericidal-permeability-increasing protein, and lysosome-associated membrane glycoprotein 2.&#x000a0;The pathogenicity of these antigens is thought to be low.<xref ref-type="bibr" rid="article-20240.r3">[3]</xref></p>
        <p>ANCA serology is positive in about 90% of GPA and MPO cases, while it is positive in about 30% of eosinophilic granulomatosis with polyangiitis cases.<xref ref-type="bibr" rid="article-20240.r4">[4]</xref>&#x000a0;Anti-PR3 antibodies are about 90% sensitive for GPA.<xref ref-type="bibr" rid="article-20240.r5">[5]</xref><xref ref-type="bibr" rid="article-20240.r6">[6]</xref>&#x000a0;Although sensitive and specific for GPA, ANCA positivity has also been noted in 15% to 20% of patients with systemic lupus erythematosus, especially those with lupus nephritis.<xref ref-type="bibr" rid="article-20240.r7">[7]</xref>&#x000a0;C-ANCA (a cytoplasmic antineutrophilic nuclear antibody with extranuclear cytoplasmic staining) is 90% PR3 reactive and 10% MPO&#x000a0;reactive; P-ANCA (a perinuclear&#x000a0;antineutrophilic nuclear antibody with staining around the nucleus) is 90% MPO reactive and 10% PR3 reactive.<xref ref-type="bibr" rid="article-20240.r8">[8]</xref>&#x000a0;Small vessel damage caused by ANCA occurs when these autoantibodies bind to granules in neutrophils. The mechanism of pathogenesis is given below:</p>
        <list list-type="bullet">
          <list-item>
            <p>Neutrophils and monocytes are activated by ANCA.</p>
          </list-item>
          <list-item>
            <p>The alternative complement pathway is subsequently activated.</p>
          </list-item>
          <list-item>
            <p>Neutrophils migrate through blood vessel walls, and inflammatory mediators are released.</p>
          </list-item>
          <list-item>
            <p>Chemoattractants are released, and more inflammatory mediators are recruited.</p>
          </list-item>
          <list-item>
            <p>Inflammation, apoptosis, necrosis, and damage to small blood vessel walls occur.<xref ref-type="bibr" rid="article-20240.r9">[9]</xref><xref ref-type="bibr" rid="article-20240.r10">[10]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Drugs Linked to ANCA&#x02013;Associated Vasculitis</bold>
</p>
        <p>Medications can induce an ANCA-associated vasculitis, usually manifesting as rapidly progressive glomerulonephritis. Specifically, a high MPO titer is common. Levamisole, which is often found in contaminated cocaine,&#x000a0;can cause the elevation of both anti-MPO&#x000a0;and anti-PR3 antibodies, along with other autoantibodies, skin lesions, and arthralgias. Treatment is the same as other ANCA-associated rapidly progressive glomerulonephritis&#x000a0;cases&#x02014;possibly with shorter induction. The most common offending medications include these:</p>
        <list list-type="bullet">
          <list-item>
            <p>Hydralazine</p>
          </list-item>
          <list-item>
            <p>Propylthiouracil and methimazole</p>
          </list-item>
          <list-item>
            <p>Allopurinol</p>
          </list-item>
          <list-item>
            <p>Sulfasalazine</p>
          </list-item>
          <list-item>
            <p>Minocycline</p>
          </list-item>
          <list-item>
            <p>Penicillamine</p>
          </list-item>
          <list-item>
            <p>Rifampicin</p>
          </list-item>
          <list-item>
            <p>Aminoguanidine</p>
          </list-item>
          <list-item>
            <p>Sofosbuvir</p>
          </list-item>
          <list-item>
            <p>Anti-tumor necrosis factor-alpha therapy for rheumatoid arthritis and ankylosing spondylitis&#x000a0;<xref ref-type="bibr" rid="article-20240.r11">[11]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20240.s3" sec-type="Specimen Requirements and Procedure">
        <title>Specimen Requirements and Procedure</title>
        <p>A blood sample is taken from a peripheral venous draw. A healthcare professional puts a rubber band around the arm and asks the patient to keep pumping the fist for some time, then palpates the vein for confirmation. An alcohol swab is applied to clean the area. After the alcohol has dried, a needle is introduced into the vein and a blood sample is collected in a test tube or a vial. After collecting the sample, the band is removed, the pressure is applied over the puncture site, hemostasis is secured, and a bandage is applied. Complications of the procedure include mild tenderness, bruising, oozing of blood, or infection at the puncture site.</p>
      </sec>
      <sec id="article-20240.s4" sec-type="Testing Procedures">
        <title>Testing Procedures</title>
        <p>After taking a blood sample, the specimen undergoes analysis by 2 techniques:</p>
        <list list-type="bullet">
          <list-item>
            <p>Indirect immunofluorescence (IIF)</p>
          </list-item>
          <list-item>
            <p>Enzyme-linked immunosorbent assay (ELISA)&#x000a0;<xref ref-type="bibr" rid="article-20240.r12">[12]</xref></p>
          </list-item>
        </list>
        <p>The indirect immunofluorescence identifies ANCA by its staining patterns inside the cytoplasm of neutrophils.<xref ref-type="bibr" rid="article-20240.r8">[8]</xref>&#x000a0;In this technique, neutrophils are fixed via ethanol onto a slide; the blood sample is then mixed on the slide with the neutrophils; if present, ANCA in the sample attaches to neutrophils on the slide. The slide is then treated with fluorochrome-stained antibodies, which react with ANCA on the slide; this forms a fluorescence pattern that is visible via a microscope. As mentioned earlier, if ANCA staining is throughout the cytoplasm, it is called a C-ANCA pattern; this is usually PR3-ANCA. If staining is only around the nucleus, it is called P-ANCA (perinuclear pattern), which usually occurs with MPO-ANCA.<xref ref-type="bibr" rid="article-20240.r8">[8]</xref>&#x000a0;On the other hand, ELISA measures the level of MPO-ANCA or PR3-ANCA patterns in an antigen-specific pattern in a blood sample.&#x000a0;</p>
        <p>Testing takes place in 2 steps. First, IIF is done, which detects the presence or absence of these autoantibodies; if the test is positive, then it is followed by ELISA.<xref ref-type="bibr" rid="article-20240.r13">[13]</xref>&#x000a0;The International Consensus Statement on Testing and Reporting ANCA&#x000a0;recommends using both techniques to detect ANCA in suspected patients.<xref ref-type="bibr" rid="article-20240.r14">[14]</xref>&#x000a0;However, the more specific ELISA antigen testing is largely replacing the use of IIF.</p>
      </sec>
      <sec id="article-20240.s5" sec-type="Interfering Factors">
        <title>Interfering Factors</title>
        <p>ANCA testing helps diagnose and monitor small vessel vasculitis, but it has some limitations, too. There is a variant of ANCA called atypical ANCA, which is associated with drug-induced ANCA-associated vasculitis, inflammatory bowel disease, and rheumatoid arthritis.<xref ref-type="bibr" rid="article-20240.r15">[15]</xref><xref ref-type="bibr" rid="article-20240.r16">[16]</xref>&#x000a0;ANCA-positive rates are also higher in type 1 diabetes mellitus than in healthy individuals.<xref ref-type="bibr" rid="article-20240.r17">[17]</xref></p>
      </sec>
      <sec id="article-20240.s6" sec-type="Results, Reporting, and Critical Findings&#x0000d;&#x0000a;">
        <title>Results, Reporting, and Critical Findings
</title>
        <p>If there is a negative IIF result, ie, ANCA is not detected, the findings are normal. However, a positive IIF result occurs when ANCA is detected; therefore, in this case, the findings are abnormal (the fluorescence pattern is also described to show whether C-ANCA or P-ANCA is present).</p>
        <p>
<bold>MPO Antibody (P-ANCA) Levels</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>&#x0003e;5.0 IU/mL = Positive</p>
          </list-item>
          <list-item>
            <p>3.5-5 IU/mL = Equivocal</p>
          </list-item>
          <list-item>
            <p>&#x0003c;3.5 IU/mL = Negative</p>
          </list-item>
        </list>
        <p>
<bold>PR3 Antibody (C-ANCA) Levels</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>&#x0003e;3.0 IU/mL = Positive</p>
          </list-item>
          <list-item>
            <p>2-3.0 IU/mL = Equivocal</p>
          </list-item>
          <list-item>
            <p>&#x0003c;2.0 IU/mL = Negative</p>
          </list-item>
        </list>
        <p>
<bold>Interpretation</bold>
</p>
        <p>Positive results for C-ANCA are mostly consistent with granulomatosis with polyangiitis. Whereas positive results with P-ANCA mostly occur in microscopic polyangiitis and eosinophilic granulomatosis with polyangiitis (or Churg-Strauss syndrome). Monitoring the titers of ANCAs is useful in monitoring the clinical course of diseases.</p>
      </sec>
      <sec id="article-20240.s7" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>Positive ANCA lab results with clinical suspicion aid in diagnosing some small vessel vasculitis, including pauci-immune small vessel vasculitides granulomatosis with polyangiitis, microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis and anti-glomerular basement disease.<xref ref-type="bibr" rid="article-20240.r1">[1]</xref><xref ref-type="bibr" rid="article-20240.r2">[2]</xref> The reappearance of ANCA after the treatment of vasculitis may indicate a relapsing disease.<xref ref-type="bibr" rid="article-20240.r18">[18]</xref><xref ref-type="bibr" rid="article-20240.r19">[19]</xref></p>
      </sec>
      <sec id="article-20240.s8" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Care coordination is pivotal in ensuring seamless and efficient patient care. Physicians, advanced clinicians, nurses, pharmacists, and other healthcare professionals must work together to streamline the patient's journey, from diagnosis through treatment and follow-up. This coordination minimizes errors, reduces delays, and enhances patient safety, ultimately leading to improved outcomes and patient-centered care.</p>
      </sec>
      <sec id="article-20240.s9">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20240&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20240">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/20240/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=20240">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-20240.s10">
        <title>References</title>
        <ref id="article-20240.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weiner</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Segelmark</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>The clinical presentation and therapy of diseases related to anti-neutrophil cytoplasmic antibodies (ANCA).</article-title>
            <source>Autoimmun Rev</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>15</volume>
            <issue>10</issue>
            <fpage>978</fpage>
            <page-range>978-82</page-range>
            <pub-id pub-id-type="pmid">27481040</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20240.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>No&#x000eb;l</surname>
                <given-names>LH</given-names>
              </name>
            </person-group>
            <article-title>[Antineutrophil cytoplasm antibodies (ANCA): description and immunopathological role].</article-title>
            <source>Ann Med Interne (Paris)</source>
            <year>2000</year>
            <month>May</month>
            <volume>151</volume>
            <issue>3</issue>
            <fpage>178</fpage>
            <page-range>178-83</page-range>
            <pub-id pub-id-type="pmid">10896969</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20240.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Walulik</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>&#x00141;ysak</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>B&#x00142;aszkiewicz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>G&#x000f3;recki</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Gomu&#x00142;ka</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>The Role of Neutrophils in ANCA-Associated Vasculitis: The Pathogenic Role and Diagnostic Utility of Autoantibodies.</article-title>
            <source>Int J Mol Sci</source>
            <year>2023</year>
            <month>Dec</month>
            <day>07</day>
            <volume>24</volume>
            <issue>24</issue>
            <pub-id pub-id-type="pmid">38139045</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20240.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peters</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Saeed</surname>
                <given-names>IT</given-names>
              </name>
              <name>
                <surname>Offiah</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jawad</surname>
                <given-names>ASM</given-names>
              </name>
            </person-group>
            <article-title>Severe localised granulomatosis with polyangiitis (Wegener's granulomatosis) manifesting with extensive cranial nerve palsies and cranial diabetes insipidus: a case report and literature review.</article-title>
            <source>BMC Neurol</source>
            <year>2018</year>
            <month>May</month>
            <day>01</day>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>59</fpage>
            <pub-id pub-id-type="pmid">29716529</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20240.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hellmich</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sanchez-Alamo</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Schirmer</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Berti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Blockmans</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cid</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Holle</surname>
                <given-names>JU</given-names>
              </name>
              <name>
                <surname>Hollinger</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Karadag</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Kronbichler</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Little</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Luqmani</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Mahr</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Merkel</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Mohammad</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Monti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mukhtyar</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Musial</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Price-Kuehne</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Segelmark</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Teng</surname>
                <given-names>YKO</given-names>
              </name>
              <name>
                <surname>Terrier</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Tomasson</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Vaglio</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vassilopoulos</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Verhoeven</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Jayne</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2024</year>
            <month>Jan</month>
            <day>02</day>
            <volume>83</volume>
            <issue>1</issue>
            <fpage>30</fpage>
            <page-range>30-47</page-range>
            <pub-id pub-id-type="pmid">36927642</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20240.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Granel</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Korkmaz</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Nouar</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Weiss</surname>
                <given-names>SAI</given-names>
              </name>
              <name>
                <surname>Jenne</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Lemoine</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hoarau</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Pathogenicity of Proteinase 3-Anti-Neutrophil Cytoplasmic Antibody in Granulomatosis With Polyangiitis: Implications as Biomarker and Future Therapies.</article-title>
            <source>Front Immunol</source>
            <year>2021</year>
            <volume>12</volume>
            <fpage>571933</fpage>
            <pub-id pub-id-type="pmid">33679731</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20240.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Xie</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Clinical features and outcomes of patients with antineutrophil cytoplasmic antibody-positive systemic lupus erythematosus.</article-title>
            <source>Ren Fail</source>
            <year>2023</year>
            <month>Dec</month>
            <volume>45</volume>
            <issue>1</issue>
            <fpage>2235431</fpage>
            <pub-id pub-id-type="pmid">37470370</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20240.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Radice</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sinico</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Antineutrophil cytoplasmic antibodies (ANCA).</article-title>
            <source>Autoimmunity</source>
            <year>2005</year>
            <month>Feb</month>
            <volume>38</volume>
            <issue>1</issue>
            <fpage>93</fpage>
            <page-range>93-103</page-range>
            <pub-id pub-id-type="pmid">15804710</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20240.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jennette</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Falk</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Pathogenesis of antineutrophil cytoplasmic autoantibody-mediated disease.</article-title>
            <source>Nat Rev Rheumatol</source>
            <year>2014</year>
            <month>Aug</month>
            <volume>10</volume>
            <issue>8</issue>
            <fpage>463</fpage>
            <page-range>463-73</page-range>
            <pub-id pub-id-type="pmid">25003769</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20240.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jennette</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Falk</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>B cell-mediated pathogenesis of ANCA-mediated vasculitis.</article-title>
            <source>Semin Immunopathol</source>
            <year>2014</year>
            <month>May</month>
            <volume>36</volume>
            <issue>3</issue>
            <fpage>327</fpage>
            <page-range>327-38</page-range>
            <pub-id pub-id-type="pmid">24777746</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20240.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hogan</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Markowitz</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Radhakrishnan</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Drug-induced glomerular disease: immune-mediated injury.</article-title>
            <source>Clin J Am Soc Nephrol</source>
            <year>2015</year>
            <month>Jul</month>
            <day>07</day>
            <volume>10</volume>
            <issue>7</issue>
            <fpage>1300</fpage>
            <page-range>1300-10</page-range>
            <pub-id pub-id-type="pmid">26092827</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20240.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Silva de Souza</surname>
                <given-names>AW</given-names>
              </name>
            </person-group>
            <article-title>Autoantibodies in systemic vasculitis.</article-title>
            <source>Front Immunol</source>
            <year>2015</year>
            <volume>6</volume>
            <fpage>184</fpage>
            <pub-id pub-id-type="pmid">25954277</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20240.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sinico</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Radice</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Antineutrophil cytoplasmic antibodies (ANCA) testing: detection methods and clinical application.</article-title>
            <source>Clin Exp Rheumatol</source>
            <year>2014</year>
            <season>May-Jun</season>
            <volume>32</volume>
            <issue>3 Suppl 82</issue>
            <fpage>S112</fpage>
            <page-range>S112-7</page-range>
            <pub-id pub-id-type="pmid">24854381</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20240.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Savige</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gillis</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Benson</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Esnault</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Falk</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Hagen</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Jayne</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Jennette</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Paspaliaris</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Pollock</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Pusey</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Savage</surname>
                <given-names>CO</given-names>
              </name>
              <name>
                <surname>Silvestrini</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>van der Woude</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Wieslander</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wiik</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA).</article-title>
            <source>Am J Clin Pathol</source>
            <year>1999</year>
            <month>Apr</month>
            <volume>111</volume>
            <issue>4</issue>
            <fpage>507</fpage>
            <page-range>507-13</page-range>
            <pub-id pub-id-type="pmid">10191771</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20240.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Savige</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Falk</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Jennette</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Wiik</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Antineutrophil cytoplasmic antibodies and associated diseases: a review of the clinical and laboratory features.</article-title>
            <source>Kidney Int</source>
            <year>2000</year>
            <month>Mar</month>
            <volume>57</volume>
            <issue>3</issue>
            <fpage>846</fpage>
            <page-range>846-62</page-range>
            <pub-id pub-id-type="pmid">10720938</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20240.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bossuyt</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Serologic markers in inflammatory bowel disease.</article-title>
            <source>Clin Chem</source>
            <year>2006</year>
            <month>Feb</month>
            <volume>52</volume>
            <issue>2</issue>
            <fpage>171</fpage>
            <page-range>171-81</page-range>
            <pub-id pub-id-type="pmid">16339302</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20240.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Omura</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tamura</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kodera</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Oba</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Toyoshima</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chiba</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sugihara</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Itabashi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shigemoto</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Araki</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Oldest-old type&#x02009;1 diabetes patient receiving insulin pump treatment with positive myeloperoxidase-antineutrophil cytoplasmic antibody complication: A case report.</article-title>
            <source>Geriatr Gerontol Int</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>19</volume>
            <issue>9</issue>
            <fpage>957</fpage>
            <page-range>957-958</page-range>
            <pub-id pub-id-type="pmid">31490005</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20240.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sinclair</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Stevens</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Role of antineutrophil cytoplasmic antibodies and glomerular basement membrane antibodies in the diagnosis and monitoring of systemic vasculitides.</article-title>
            <source>Ann Clin Biochem</source>
            <year>2007</year>
            <month>Sep</month>
            <volume>44</volume>
            <issue>Pt 5</issue>
            <fpage>432</fpage>
            <page-range>432-42</page-range>
            <pub-id pub-id-type="pmid">17761028</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20240.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stegeman</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Predictive value of antineutrophil cytoplasmic antibodies in small-vessel vasculitis: is the glass half full or half empty?</article-title>
            <source>J Rheumatol</source>
            <year>2005</year>
            <month>Nov</month>
            <volume>32</volume>
            <issue>11</issue>
            <fpage>2075</fpage>
            <page-range>2075-7</page-range>
            <pub-id pub-id-type="pmid">16265681</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
